109 filings
ARS
2023 FY
RXRX
Recursion Pharmaceuticals Inc - Ordinary Shares
23 Apr 24
Annual report to shareholders
5:29pm
DEFA14A
RXRX
Recursion Pharmaceuticals Inc - Ordinary Shares
23 Apr 24
Additional proxy soliciting materials
5:16pm
8-K
RXRX
Recursion Pharmaceuticals Inc - Ordinary Shares
16 Apr 24
Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer
8:04am
8-K
zathw9 5v0pi6
27 Feb 24
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2023 Financial Results
4:09pm
8-K
03d2xis70
7 Feb 24
Departure of Directors or Certain Officers
4:56pm
8-K
b5g9slunmf6l22re58
31 Jan 24
Amendments to Articles of Incorporation or Bylaws
4:40pm
8-K
3r2kt8w
8 Jan 24
Regulation FD Disclosure
7:59am
8-K
vydsmwah
20 Dec 23
Regulation FD Disclosure
8:01am
8-K
r7a wvfobkg1v5a9x
15 Dec 23
Other Events
8:41am
424B7
n1kr6u
15 Dec 23
Prospectus with selling stockholder info
8:38am
8-K
vh29rrpa
9 Nov 23
Recursion Provides Business Updates and Reports Third Quarter 2023 Financial Results
8:03am
8-K
3cwz9ahn
2 Oct 23
Decoding Biology To Radically Improve Lives Early October 2023
7:48am
8-K
xy8a xurlo0ou
5 Sep 23
Recursion Announces Completion of Phase 1 Study for REC-3964 for Clostridioides Difficile Infection
8:01am
8-K/A
csufdmcf
11 Aug 23
Submission of Matters to a Vote of Security Holders
4:12pm
424B5
ub4mny6 bv5
8 Aug 23
Prospectus supplement for primary offering
8:13am
424B7
9db9vx882tdjy8
8 Aug 23
Prospectus with selling stockholder info
8:11am